Cargando…

Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells

Humans are infected with two types of EBV (Type 1 (T1) and Type 2 (T2)) that differ substantially in their EBNA2 and EBNA 3A/B/C latency proteins and have different phenotypes in B cells. T1 EBV transforms B cells more efficiently than T2 EBV in vitro, and T2 EBV-infected B cells are more lytic. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bristol, Jillian A., Brand, Joshua, Ohashi, Makoto, Eichelberg, Mark R., Casco, Alejandro, Nelson, Scott E., Hayes, Mitchell, Romero-Masters, James C., Baiu, Dana C., Gumperz, Jenny E., Johannsen, Eric C., Dinh, Huy Q., Kenney, Shannon C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041801/ https://www.ncbi.nlm.nih.gov/pubmed/35472072 http://dx.doi.org/10.1371/journal.ppat.1010453

Ejemplares similares

B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection
por: Romero-Masters, James C., et al.
Publicado: (2020)

An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model
por: Romero-Masters, James C., et al.
Publicado: (2018)

Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription
por: Ali, Ahmed, et al.
Publicado: (2022)

Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells
por: Van Sciver, Nicholas, et al.
Publicado: (2021)

EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice
por: Li, Chunrong, et al.
Publicado: (2020)

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
por: Bilger, Andrea, et al.
Publicado: (2017)

A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection
por: Bristol, Jillian A., et al.
Publicado: (2018)

EBV Reactivation from Latency Is a Degrading Experience for the Host
por: Casco, Alejandro, et al.
Publicado: (2023)

Contribution of the KSHV and EBV lytic cycles to tumourigenesis
por: Manners, Oliver, et al.
Publicado: (2018)

Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes
por: Singh, Deo R., et al.
Publicado: (2022)

Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ
por: Singh, Deo R., et al.
Publicado: (2023)

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
por: Ramayanti, Octavia, et al.
Publicado: (2018)

Inhibition of autophagy in EBV-positive Burkitt's lymphoma cells enhances EBV lytic genes expression and replication
por: De Leo, A, et al.
Publicado: (2015)

Conquering the Nuclear Envelope Barriers by EBV Lytic Replication
por: Lee, Chung-Pei, et al.
Publicado: (2021)

Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma
por: Choi, Su Jin, et al.
Publicado: (2019)

ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells
por: Van Sciver, Nicholas, et al.
Publicado: (2021)

Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy
por: Granato, Marisa, et al.
Publicado: (2017)

Complexities associated with expression of Epstein–Barr virus (EBV) lytic origins of DNA replication
por: Xue, Shao-An, et al.
Publicado: (2007)

Epstein–Barr Virus (EBV) Rta-Mediated EBV and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivations in 293 Cells
por: Chen, Yen-Ju, et al.
Publicado: (2011)

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
por: Zhang, Xi, et al.
Publicado: (2023)

C/EBPbeta mediates bortezomib-induced EBV and KSHV lytic gene expression
por: O’Farrell, Courtney, et al.
Publicado: (2010)

Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells
por: Nawandar, Dhananjay M., et al.
Publicado: (2015)

CAGE-seq analysis of Epstein-Barr virus lytic gene transcription: 3 kinetic classes from 2 mechanisms
por: Djavadian, Reza, et al.
Publicado: (2018)

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
por: Li, Hongde, et al.
Publicado: (2018)

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies
por: Choi, Chung King, et al.
Publicado: (2015)

Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection
por: Lam, Janice K. P., et al.
Publicado: (2018)

Epstein-Barr Virus Infection Promotes Epithelial Cell Growth by Attenuating Differentiation-Dependent Exit from the Cell Cycle
por: Eichelberg, Mark R., et al.
Publicado: (2019)

Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus’s natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter
por: Kraus, Richard J., et al.
Publicado: (2017)

Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma
por: Farina, Antonella, et al.
Publicado: (2021)

Burkitt's lymphoma: differential killing of Epstein-Barr virus (EBV) (+) and EBV(-) Burkitt lymphoma cells in vitro and dose-dependent lytic induction by bortezomib in vivo
por: Dufresne, AL, et al.
Publicado: (2009)

PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model
por: Ma, Shi-Dong, et al.
Publicado: (2016)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

Estrogen induces the expression of EBV lytic protein ZEBRA, a marker of poor prognosis in nasopharyngeal carcinoma
por: Dochi, Hirotomo, et al.
Publicado: (2022)

Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus
por: Giunco, S, et al.
Publicado: (2015)

Attenuation of IFN signaling due to m(6)A modification of the host epitranscriptome promotes EBV lytic reactivation
por: Bose, Dipayan, et al.
Publicado: (2023)

Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein–Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers
por: Yiu, Stephanie Pei Tung, et al.
Publicado: (2018)

DNA Damage Signaling Is Induced in the Absence of Epstein—Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA
por: Wang'ondu, Ruth, et al.
Publicado: (2015)

(−)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes
por: Li, Hongde, et al.
Publicado: (2021)

Rheumatoid arthritis patient antibodies highly recognize IL-2 in the immune response pathway involving IRF5 and EBV antigens
por: Bo, Marco, et al.
Publicado: (2018)

EBV Exploits RNA m(6)A Modification to Promote Cell Survival and Progeny Virus Production During Lytic Cycle
por: Yanagi, Yusuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h6jmgb0c73e6gt4bq81tgg45io